KDR and gastroesophageal junction adenocarcinoma: Ramucirumab (Cyramza®) is a fully humanized IgG1 antibody with a weight of 147 kDa, which targets the extracellular binding domain of VEGFR-2 to disturb the potent VEGF signal in tumor angiogenesis (Table 1).382,383 As the first antibody targeted VEGFR-2, ramucirumab significantly improved the median OS (5.2 months vs. placebo 3.8 months) and PFS (2.1 months vs. placebo 1.3 months) rates of patients (adults with advanced or unresectable gastric and gastroesophageal junction adenocarcinoma) in a prospective, double-blind and placebo-controlled a phase III REGARD clinical trial.